Advances in Immunotherapy of Cancer
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccination Against Cancer and Chronic Diseases".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 2238
Special Issue Editors
Interests: immunology and microbiology; modern biotechnology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer vaccines have emerged as a transformative approach in oncology, leveraging the immune system to target and eliminate malignant cells. Based on the deep understanding of tumor immunity and great improvements in biotechnology and artificial intellengence (AI), cancer vaccines have become increasingly prominent in cancer immunotherapies.
We are pleased to invite you to contribute to this Special Issue, Advances in Immunotherapy of Cancer, of the Vaccines journal, aimed at reporting new advances in cancer vaccines and cancer immunotherapy, such as new cancer vaccines, new technology for cancer vaccine development, and the immunomechanism of cancer vaccines.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- immunomechanism of cancer vaccines;
- mRNA-based cancer vaccines;
- tumor neoantigens;
- peptide-based vaccines;
- adjuvant;
- antigen finding and AI-driven antigen prediction;
- combination therapies;
- vaccine delivery.
We look forward to receiving your contributions.
Prof. Dr. Li Ye
Dr. Jiajun Fan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer vaccines
- neoantigen
- immunotherapy
- cancer microenviroment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
